Cadrenal Therapeutics(CVKD) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update Announces strategic clinical trial plans for tecarfarin in patients with End-Stage Kidney Disease (ESKD) transitioning to dialysis Highlights from the Quarter Ended June 30, 2025, and Other Recent Events: Clinical Trial Developments In August 2025, Cadrenal announced plans to initiate a clinical trial for its late-stage drug candidate, tecarfarin, in patients with ESKD who are transitioning to dial ...